IMPEDIMED LIMITED

0.00%

1.7¢

Market Cap $34.65M

Healthcare Medical Devices

ImpediMed Limited is an Australia-based medical technology company. The Company uses... ImpediMed Limited is an Australia-based medical technology company. The Company uses bioimpedance spectroscopy (BIS) technology to generate data to maximize patient health. The Company designs and manufactures medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the noninvasive clinical assessment and monitoring of fluid status and tissue composition. The Company’s SOZO Digital Health Platform is a Food and Drug Administration (FDA)-cleared bioimpedance spectroscopy (BIS) solution for the clinical assessment of lymphedema. Its SOZO Applications include L-Dex Analysis for Lymphedema, BodyComp Analysis, Segmental BodyComp Analysis, and HF-Dex Analysis for Heart Failure. Its product SFB7 measures fluid status and tissue composition for clinical and research applications. Its ImpediVET is a single-channel, tetrapolar bioimpedance spectroscopy (BIS) device that measures fluid status and tissue composition for veterinary applications.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Latest Threads

Tag

Subject

IPD

Ann: FY26 H1 Results Investor Presentation

12/03/26

9.1K

12/03/26

Last post Newbe01

9.1K

IPD

Ann: Appointment of Independent Non-executive Director

02/03/26

5.5K

02/03/26

Last post BBInvestorClub

5.5K

IPD

Ann: FY26 Half Year Financial Results

26/02/26

565

26/02/26

Last post sundowner1234

565

IPD

Ann: Appendix 4D and Interim Financial Report

26/02/26

176

26/02/26

Last post

ASX News

176

IPD

Ann: Initial Director's Interest Notice - Mr Erik Anderson

25/02/26

202

25/02/26

Last post

ASX News

202

IPD

Ann: Quarterly Activities Report and Appendix 4C - Dec-2025

2 3

25/02/26

127

24K

25/02/26

Last post kpt3891

127

24K

IPD

Ann: Change of Director's Interest Notice - Ms Emmanuel-Donnelly

23/02/26

9.9K

23/02/26

Last post Newbe01

9.9K

IPD

Cancer breakthroughs in mass

08/02/26

2.1K

08/02/26

Last post Acclivity

2.1K

See All Discussions

Timeline

FY26 H1 Results Investor Presentation
03 Mar 08:28	Share

FY26 Half Year Financial Results
26 Feb 08:30	Share

Appendix 4D and Interim Financial Report
26 Feb 08:30	Share

Initial Director's Interest Notice - Mr Erik Anderson
25 Feb 16:01	Share

Appointment of Independent Non-executive Director
25 Feb 15:39	Share

Change of Director's Interest Notice - Ms Emmanuel-Donnelly
09 Feb 15:07	Share

Investor Presentation
29 Jan 08:18	Share

Quarterly Activities Report and Appendix 4C - Dec-2025
29 Jan 08:18	Share

Q2 FY26 Quarterly Results Investor Webinar
27 Jan 08:25	Share

Update - Application for quotation of securities - IPD
16 Jan 17:23	Share

Change of Director's Interest Notice - Mr Andrew Grant
16 Jan 14:21	Share

Change of Director's Interest Notice - Ms Emmanuel-Donnelly
16 Jan 14:20	Share

Change of Director's Interest Notice - Ms Janelle Delaney
16 Jan 14:18	Share

Change of Director's Interest Notice - Ms Fiona Bones
16 Jan 14:17	Share

Application for quotation of securities - IPD
16 Jan 14:13	Share

Notification of cessation of securities - IPD
14 Jan 15:29	Share

Application for quotation of securities - IPD
23 Dec 16:24	Share

Positive Momentum in US Reimbursement Coverage Continues
04 Dec 08:18	Share

Receipt of R&D tax incentive refund
24 Nov 17:04	Share

AGM - Results of Meeting
18 Nov 13:45	Share

AGM - CEO's Presentation
18 Nov 10:24	Share

AGM - Chair's Address
18 Nov 10:21	Share

Change of Director's Interest Notice - Mr Andrew Grant
06 Nov 20:24	Share

Change of Director's Interest Notice - Ms Emmanuel-Donnelly
06 Nov 20:24	Share

Change of Director's Interest Notice - Ms Janelle Delaney
06 Nov 20:23	Share

Change of Director's Interest Notice - Ms Fiona Bones
06 Nov 20:21	Share

Application for quotation of securities - IPD
06 Nov 08:20	Share

Application for quotation of securities - IPD
06 Nov 08:20	Share

Investor Presentation
30 Oct 08:19	Share

Quarterly Activities Report and Appendix 4C - Sep-2025 Qtr
30 Oct 08:19	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 1.7¢		Change 0.000(0.00%)		Mkt cap ! $34.65M

Open	High	Low	Volume
1.7¢	1.7¢	1.7¢	2.515M

Buyers (Bids)

Vol.	Price($)
4714597	1.6¢

Sellers (Offers)

Price($)	Vol.
1.8¢	827901

Last trade - 16.11pm 12/03/2026 (20 minute delay)

IPD (ASX) Chart

IMPEDIMED LIMITED

Corporate Spotlight
Not Yet Available

Latest Threads

Meet Syntara: A Clinical-Stage Biotech with Multiple Shots on Goal Across Blood Cancer & Fibrosis

Timeline

Featured News

Latest Articles

ImpediMed (ASX:IPD) makes strategic leadership changes, with hopes for growth

ImpediMed (ASX: IPD) has undergone significant leadership and board changes in a bid to maximize growth potential and streamline operations.

ImpediMed (ASX:IPD) shares soar on NCCN Guidelines update

Impedimed (ASX:IPD) shares soared on Monday after the US National Comprehensive Cancer Network (NCCN) recommended regular screenings with bioimpedance spectroscopy (BIS).

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News

IMPEDIMED LIMITED

Corporate SpotlightNot Yet Available

Latest Threads

Meet Syntara: A Clinical-Stage Biotech with Multiple Shots on Goal Across Blood Cancer & Fibrosis

Timeline

Featured News

Latest Articles

ImpediMed (ASX:IPD) makes strategic leadership changes, with hopes for growth

ImpediMed (ASX: IPD) has undergone significant leadership and board changes in a bid to maximize growth potential and streamline operations.

ImpediMed (ASX:IPD) shares soar on NCCN Guidelines update

Impedimed (ASX:IPD) shares soared on Monday after the US National Comprehensive Cancer Network (NCCN) recommended regular screenings with bioimpedance spectroscopy (BIS).

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News

Corporate Spotlight
Not Yet Available